慢性胰腺炎的管道干预:对血糖控制和内分泌缺陷管理的影响
Sidharth Harindranath1, Biswa R Patra1, Abu A Ansari1
1Department of Gastroenterology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, IND.
Cureus
|September 9, 2024
概括
胰腺内分泌疗法在三分之一的慢性胰腺炎患者中改善了内分泌功能. 早期干预可以提高精选个体的血糖控制和糖尿病管理.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 医疗干预 医疗干预
背景情况:
- 胰腺内疗是为慢性胰腺炎 (CP) 疼痛管理而建立的.
- 它对内分泌功能不全的作用,一种常见的CP并发症,理解程度较低.
研究的目的:
- 评估胰腺内疗对胰腺癌患者血糖状况和糖尿病管理的影响.
主要方法:
- 对141名接受内镜逆行胆血管细胞造影的CP患者的回顾性审查.
- 分析糖化血红蛋白 (HbA1c) 水平和糖尿病药物需求在内疗前后.
主要成果:
- 42.5%的患者有先前存在的内分泌功能障碍 (平均HbA1c 8.46 g/dl).
- 在内分泌疗法后,三分之一的患者表现出改善的内分泌功能.
- 在之前需要胰岛素治疗的患者中,31.9%的患者停止了胰岛素治疗.
结论:
- 胰腺内分泌疗法可以导致胰腺癌患者的一个子集的血糖控制显著改善.
- 早期的管道干预可能会对某些CP患者的糖尿病管理产生积极影响,特别是那些患有异常性胰腺炎且没有表皮功能不全的患者.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
71
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
71
Chronic Pancreatitis I: Introduction
78
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
78
Acute Pancreatitis II: Clinical Manifestations and Management
96
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
96
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


